Search





Search





Markets
/
Stocks
/
hims
/

Hims & Hers Health Inc

HIMS

Add to Watchlist

26.780USD

+1.780+7.12%

Market hours （ET）Quotes delayed by 15 min

6.18BMarket Cap

LossP/E TTM

Hims & Hers Health Inc

26.780

+1.780+7.12%

Overview

Financials

Discussions

Analysis

Company

View Detailed Chart

TradingKey Chart

Intraday

30m

Today

+7.12%

5 Days

-15.47%

1 Month

-19.80%

6 Months

-10.34%

Year to Date

-17.52%

1 Year

-55.57%

Key Figures

24.980Open

26.905High

11.24MVolume

LossP/E TTM

37.11P/E Dynamic

--Dividend TTM

4.87%Turnover Ratio

25.000Prev. Close

24.240Low

145.30MTurnover

49.02P/E Static

13.85P/B

0.00%Div Yield TTM

-0.84%ROA

70.43052wk High

0.86Volume Ratio

126.04MNet Profit

230.70MShares

-0.0557EPS TTM

2.38Beta

-2.66%ROE

13.74052wk Low

10.66%Amplitude

69.94%Gross Margin

6.18BMarket Cap

-5.98Reward/Risk

4.67%Risk Rate

TradingKey Stock Score of Hims & Hers Health Inc

Currency: USD Updated: 2026-07-29

Key Insights

Hims & Hers Health Inc's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 26 out of 75 in the Healthcare Providers & Services industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 30.19.In the medium term, the stock price is expected to remain stable.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Hims & Hers Health Inc's Score

Industry at a Glance

Industry Ranking

26 / 75

Overall Ranking

107 / 4277

Industry

Healthcare Providers & Services

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Hims & Hers Health Inc Highlights

StrengthsRisks

Hims & Hers Health, Inc. provides a consumer-first platform, which helps customers to fulfill their health and wellness needs. Its platform includes access to a provider network, a clinically focused electronic medical record system, digital prescriptions, cloud pharmacy fulfillment, and personalization capabilities. Its digital platform enables access to treatments for a range of chronic conditions, including those related to sexual health, hair loss, dermatology, mental health, and weight loss. It connects patients to licensed healthcare professionals who can prescribe medications when appropriate and prescriptions are fulfilled online through licensed pharmacies on a subscription basis. It also offers access to a range of health and wellness products designed to meet individual needs, which can include curated prescription and non-prescription products. Through its mobile applications, consumers can access a range of educational programs, wellness content, and other services.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 169.22% year-on-year.

Undervalued

The company’s latest PE is -448.91, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 208.41M shares, decreasing 15.42% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 0.00 shares of this stock.

Analyst Rating

Based on 16 analysts

Hold

Current Rating

30.187

Target Price

-0.17%

Upside Space

Hims & Hers Health Inc News

PPI Report April 2026: How Inflation Data Is Moving HIMS, CEG, and PLUG Stock Today

TradingKey - Wall Street is navigating a two-day inflation gauntlet. Tuesday's CPI print for April arrived hotter than expected, rattling equity markets from telehealth to nuclear energy. Wednesday morning brings the Producer Price Index (PPI) for April — and if today's Consumer Price Index is any g

TradingKeyWed, May 13

Hims & Hers (HIMS) Q1 2026 Earnings Preview: GLP-1 Pivot, Subscriber Surge & Stock Catalyst Watch

TradingKey - Hims & Hers Health (HIMS) is due to release its Q1 2026 results after the closing bell today. Below, we outline what investors should watch for in today's report.

TradingKeyTue, May 12

Hims & Hers Soars 64% in Three Days as Novo Nordisk Deal Opens Door to GLP-1 Market

TradingKey - Shares of Hims & Hers Health (HIMS.US) surged nearly 64% cumulatively over the first three trading days of this week, with an intraday rally of over 10% on Wednesday.

TradingKeyThu, Mar 12

Investing in Health Stock: Will GLP-1 Pill Copycat Restrictions Derail Hims & Hers? Is HIMS Still a Good Choice in 2026?

Hims & Hers' subscription-based business model, coupled with tailored treatment regimens, allows users to maintain lasting engagement, a critical aspect of the company’s growth narrative and a reason why some see Hims & Hers stock as a play on long-term digital health as opposed to a traditional pha

TradingKeyTue, Feb 10

Hims & Hers Health Inc (HIMS): The Opportunity is still Strong and Potent

TradingKey - Despite the whole controversy with NVO, we believe HIMS is able to achieve 6 million subscribers and $6 billion of revenue by 2030, due to the large opportunity of growth for the telehealth industry, early investments in logistics capabilities and ability to upsell their patients.

TradingKeyMon, Sep 1

Hims & Hers: A Game-Changer in Telehealth or Just Another Fad?

Explore the exciting world of Hims & Hers (NYSE: HIMS) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!

OtherFri, Aug 8